FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis
FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis Print this page SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval… Read More »